Seattle Genetics Presents Adcetris Trials Data

Biopharmaceutical company Seattle Genetics has been busy this weekend, presenting data from a number of trials at the American Society of Clinical Oncology's annual meeting in Chicago.

They include two studies involving lymphoma subtypes:

Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study.

This ongoing phase II trial is investigating patients who previously responded to treatment with Adcetris, then discontinued treatment and subsequently experienced disease progression or relapse.

23 evaluable patients are enrolled, including 16 with Hodgkin lymphoma (HL) and eight with systemic anaplastic large cell lymphoma (sALCL).

Patients had received a median of four prior systemic therapies. 70 percent achieved an objective response, including nine complete remissions (CRs) and seven partial remissions (PRs). Median duration of retreatment objective response was 8.8 months.

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study

This phase II clinical trial involves patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma and other less common lymphoma subtypes (and is still enrolling). The trial was designed to evaluate the activity, duration of response and safety profile of Adcetris in this patient population. 28 patients had been enrolled when the data was analyzed, including 18 with B-cell malignancies and ten with T-cell malignancies. The median number of prior systemic therapies was three. Notably, four of the seven DLBCL patients achieved objective response, including two who had a complete response.

Source: MarketWatch